Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature.
complications
daratumumab
fungal infection
mould
multiple myeloma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
01
2022
accepted:
10
06
2022
entrez:
5
8
2022
pubmed:
6
8
2022
medline:
6
8
2022
Statut:
epublish
Résumé
Life expectancy of multiple myeloma (MM) patients has improved in last years due to the advent of anti-CD38 monoclonal antibodies in combination with immunomodulators and proteasome inhibitors. However, morbidity and mortality related to infections remain high and represent a major concern. This paper describes the "real life" risk of invasive fungal infections (IFI) in patients treated with daratumumab-based therapy and reviews the relevant literature. In a series of 75 patients we only observed three cases of fungal pneumonia. Unfortunately, the early signs and symptoms were not specific for fungal infection. Diagnostic imaging, microbiology and patient history, especially previous therapies, are critical in the decision to start antifungal treatment. Recognising the subgroup of MM patients with high risk of IFI can increase the rate of diagnosis, adequate treatment and MM-treatment recovery.
Identifiants
pubmed: 35928865
doi: 10.3389/fonc.2022.867301
pmc: PMC9344135
doi:
Types de publication
Case Reports
Langues
eng
Pagination
867301Informations de copyright
Copyright © 2022 Farina, Ferla, Marktel, Clerici, Mastaglio, Perini, Oltolini, Greco, Aletti, Assanelli, Lupo-Stanghellini, Bernardi, Corti, Ciceri and Marcatti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Hematol. 2020 Aug;99(8):1813-1822
pubmed: 32607596
PLoS One. 2019 Feb 13;14(2):e0211927
pubmed: 30759167
Leuk Lymphoma. 2006 Aug;47(8):1570-82
pubmed: 16966269
Haematologica. 2015 Jan;100(1):107-13
pubmed: 25344526
Front Immunol. 2017 Nov 22;8:1623
pubmed: 29213274
Front Oncol. 2021 Feb 15;10:575168
pubmed: 33659205
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Blood Rev. 2018 Mar;32(2):106-115
pubmed: 28958644
Lancet. 2020 Jan 11;395(10218):132-141
pubmed: 31836199
Clin Infect Dis. 2009 Oct 15;49(8):1211-25
pubmed: 19769539
Clin Infect Dis. 2012 Jun;54(12):e173-83
pubmed: 22423136
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Lancet. 2020 Jul 18;396(10245):186-197
pubmed: 32682484
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
Br J Haematol. 2019 Apr;185(1):187-189
pubmed: 29974956
Ther Adv Hematol. 2021 Jul 28;12:20406207211035272
pubmed: 34377384
Clin Microbiol Infect. 2011 Dec;17(12):1882-9
pubmed: 21668573
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Crit Rev Oncol Hematol. 2021 Feb;158:103203
pubmed: 33388453
Clin Infect Dis. 2010 Dec 1;51(11):1273-80
pubmed: 21034199
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
Clin Infect Dis. 2000 Jan;30(1):41-6
pubmed: 10619731
Br J Haematol. 2005 Jun;129(5):569-82
pubmed: 15916679
Ann Hematol. 2018 Nov;97(11):2163-2171
pubmed: 29938309
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S83-S94
pubmed: 29572070
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
Haematologica. 2006 Aug;91(8):1068-75
pubmed: 16885047
Bone Marrow Transplant. 2009 Jan;43(2):121-6
pubmed: 18794866
BMC Cancer. 2021 Jun 26;21(1):730
pubmed: 34172037
Haematologica. 2017 Mar;102(3):e108-e111
pubmed: 27856512
Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):537-542
pubmed: 27601001
Haematologica. 2015 Jan;100(1):e28-31
pubmed: 25304609